OncoTherapy Science, Inc. (4564.T)
JPY 26.0
(-3.7%)
JPY 26.0
(-3.7%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -177.71 Million JPY | -526.34% |
| 2022 | 41.68 Million JPY | -63.41% |
| 2021 | 113.91 Million JPY | 482.91% |
| 2020 | 19.54 Million JPY | 138.99% |
| 2019 | -50.11 Million JPY | 98.03% |
| 2018 | -2.54 Billion JPY | 6.41% |
| 2017 | -2.72 Billion JPY | -2.62% |
| 2016 | -2.65 Billion JPY | -1980.78% |
| 2015 | 140.97 Million JPY | 108.68% |
| 2014 | -1.62 Billion JPY | 52.98% |
| 2013 | -3.45 Billion JPY | -308.5% |
| 2012 | -845.58 Million JPY | -113.59% |
| 2011 | 6.22 Billion JPY | 16.09% |
| 2010 | 5.36 Billion JPY | 1.97% |
| 2009 | 5.25 Billion JPY | 58.0% |
| 2008 | 3.32 Billion JPY | 68.67% |
| 2007 | 1.97 Billion JPY | 145.23% |
| 2006 | 804.49 Million JPY | -30.93% |
| 2005 | 1.16 Billion JPY | -26.28% |
| 2004 | 1.58 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -181 Million JPY | -365.44% |
| 2023 Q3 | -50.43 Million JPY | -8.15% |
| 2023 Q2 | -46.63 Million JPY | -11.67% |
| 2023 Q1 | -41.76 Million JPY | -172.67% |
| 2023 Q4 | -38.88 Million JPY | 22.89% |
| 2023 FY | -177.71 Million JPY | -526.34% |
| 2022 Q3 | -19.05 Million JPY | 55.87% |
| 2022 Q4 | 57.46 Million JPY | 401.62% |
| 2022 FY | 41.68 Million JPY | -63.41% |
| 2022 Q2 | -43.17 Million JPY | -192.96% |
| 2022 Q1 | 46.44 Million JPY | -59.52% |
| 2021 Q4 | 114.73 Million JPY | 609.13% |
| 2021 Q3 | -22.53 Million JPY | -532.22% |
| 2021 FY | 113.91 Million JPY | 482.91% |
| 2021 Q2 | 5.21 Million JPY | -68.39% |
| 2021 Q1 | 16.49 Million JPY | -82.51% |
| 2020 Q3 | -23.35 Million JPY | -27.53% |
| 2020 FY | 19.54 Million JPY | 138.99% |
| 2020 Q4 | 94.34 Million JPY | 503.89% |
| 2020 Q1 | -33.12 Million JPY | -150.5% |
| 2020 Q2 | -18.31 Million JPY | 44.71% |
| 2019 Q2 | -37.61 Million JPY | 22.05% |
| 2019 Q3 | -29.84 Million JPY | 20.66% |
| 2019 Q1 | -48.25 Million JPY | 92.26% |
| 2019 FY | -50.11 Million JPY | 98.03% |
| 2019 Q4 | 65.59 Million JPY | 319.79% |
| 2018 Q2 | -928 Million JPY | -43.75% |
| 2018 FY | -2.54 Billion JPY | 6.41% |
| 2018 Q4 | -623.28 Million JPY | -78.3% |
| 2018 Q1 | -645.55 Million JPY | 8.94% |
| 2018 Q3 | -349.57 Million JPY | 62.33% |
| 2017 Q1 | -524.08 Million JPY | 28.32% |
| 2017 FY | -2.72 Billion JPY | -2.62% |
| 2017 Q4 | -708.93 Million JPY | 1.98% |
| 2017 Q3 | -723.22 Million JPY | 5.4% |
| 2017 Q2 | -764.51 Million JPY | -45.88% |
| 2016 FY | -2.65 Billion JPY | -1980.78% |
| 2016 Q2 | -649 Million JPY | 5.34% |
| 2016 Q4 | -731.11 Million JPY | -24.85% |
| 2016 Q3 | -585.6 Million JPY | 9.77% |
| 2016 Q1 | -685.6 Million JPY | -7.12% |
| 2015 Q4 | -640.06 Million JPY | 8.34% |
| 2015 FY | 140.97 Million JPY | 108.68% |
| 2015 Q1 | -573.76 Million JPY | -108.4% |
| 2015 Q2 | -704.01 Million JPY | -22.7% |
| 2015 Q3 | -698.26 Million JPY | 0.82% |
| 2014 Q1 | -249.06 Million JPY | 65.56% |
| 2014 FY | -1.62 Billion JPY | 52.98% |
| 2014 Q2 | -655.34 Million JPY | -163.12% |
| 2014 Q3 | -444.3 Million JPY | 32.2% |
| 2014 Q4 | -275.32 Million JPY | 38.03% |
| 2013 Q1 | -994.85 Million JPY | -285.58% |
| 2013 Q3 | -828.73 Million JPY | 8.67% |
| 2013 FY | -3.45 Billion JPY | -308.5% |
| 2013 Q4 | -723.19 Million JPY | 12.74% |
| 2013 Q2 | -907.44 Million JPY | 8.79% |
| 2012 Q2 | -316.54 Million JPY | -189.35% |
| 2012 Q1 | 354.28 Million JPY | -92.57% |
| 2012 FY | -845.58 Million JPY | -113.59% |
| 2012 Q3 | -389.4 Million JPY | -23.02% |
| 2012 Q4 | 536.08 Million JPY | 237.67% |
| 2011 Q4 | 4.76 Billion JPY | 894.83% |
| 2011 Q1 | 337.97 Million JPY | -77.89% |
| 2011 Q2 | 640.17 Million JPY | 89.41% |
| 2011 Q3 | 479.14 Million JPY | -25.15% |
| 2011 FY | 6.22 Billion JPY | 16.09% |
| 2010 Q1 | 273.59 Million JPY | -89.5% |
| 2010 Q2 | 1.56 Billion JPY | 473.72% |
| 2010 Q3 | 1.98 Billion JPY | 26.76% |
| 2010 Q4 | 1.52 Billion JPY | -23.19% |
| 2010 FY | 5.36 Billion JPY | 1.97% |
| 2009 Q1 | 296.49 Million JPY | -89.54% |
| 2009 FY | 5.25 Billion JPY | 58.0% |
| 2009 Q4 | 2.6 Billion JPY | 71.74% |
| 2009 Q3 | 1.51 Billion JPY | 81.11% |
| 2009 Q2 | 837.81 Million JPY | 182.57% |
| 2008 FY | 3.32 Billion JPY | 68.67% |
| 2008 Q3 | 270.69 Million JPY | 0.0% |
| 2008 Q4 | 2.83 Billion JPY | 947.09% |
| 2007 FY | 1.97 Billion JPY | 145.23% |
| 2006 FY | 804.49 Million JPY | -30.93% |
| 2005 FY | 1.16 Billion JPY | -26.28% |
| 2004 FY | 1.58 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | 109.447% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | 321.301% |
| GNI Group Ltd. | 22.43 Billion JPY | 100.792% |
| Linical Co., Ltd. | 3.77 Billion JPY | 104.704% |
| Trans Genic Inc. | 2.24 Billion JPY | 107.901% |
| MEDINET Co., Ltd. | 98.25 Million JPY | 280.88% |
| Soiken Holdings Inc. | 2.48 Billion JPY | 107.159% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | 113.749% |
| AnGes, Inc. | -3.06 Billion JPY | 94.202% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 101.839% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | 134.355% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | 260.17% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | 112.251% |
| CanBas Co., Ltd. | -984 Million JPY | 81.939% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | 145.371% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | 110.731% |
| Chiome Bioscience Inc. | 398.59 Million JPY | 144.586% |
| Kidswell Bio Corporation | 1.03 Billion JPY | 117.098% |
| PeptiDream Inc. | 17.21 Billion JPY | 101.032% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | 680.683% |
| Ribomic Inc. | -10.5 Million JPY | -1592.23% |
| SanBio Company Limited | -14.5 Million JPY | -1125.303% |
| Healios K.K. | 108 Million JPY | 264.554% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | -52016.716% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | -200.982% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | -11653.836% |
| StemRIM | -44.34 Million JPY | -300.726% |
| CellSource Co., Ltd. | 3.18 Billion JPY | 105.58% |
| FunPep Company Limited | -680.28 Million JPY | 73.876% |
| Kringle Pharma, Inc. | 69.25 Million JPY | 356.632% |
| Stella Pharma Corporation | 217.29 Million JPY | 181.785% |
| TMS Co., Ltd. | -6.95 Million JPY | -2457.094% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | 156.497% |
| Cuorips Inc. | 9.63 Million JPY | 1945.27% |
| K Pharma,Inc. | 910 Million JPY | 119.529% |
| Takara Bio Inc. | 25.45 Billion JPY | 100.698% |
| ReproCELL Incorporated | 1.1 Billion JPY | 116.087% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | 114.871% |
| StemCell Institute Inc. | 1.57 Billion JPY | 111.277% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 110.662% |
| CellSeed Inc. | 107.15 Million JPY | 265.851% |